相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia
Donald C. Goff et al.
NEUROPSYCHOPHARMACOLOGY (2008)
The Cognitive and Negative Symptoms in Schizophrenia, Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments
Robert W. Buchanan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Sandeep T. Patil et al.
NATURE MEDICINE (2007)
The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients:: A double-blind, placebo-controlled study
R. Zoccali et al.
SCHIZOPHRENIA RESEARCH (2007)
Novel therapeutics schizophrenia: Targeting glycine modulation of NMDA glutamate receptors
Stephen M. Stahl
CNS SPECTRUMS (2007)
Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial
Shahin Akhondzadeh et al.
SCHIZOPHRENIA RESEARCH (2007)
Decreased T cellular immune response in schizophrenic patients
Michael Riedel et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2007)
Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry
Paolo Guidetti et al.
GLIA (2007)
Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain
G. Ceresoli-Borroni et al.
JOURNAL OF NEURAL TRANSMISSION (2006)
Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder
CL Miller et al.
BRAIN RESEARCH (2006)
The neurochemica circuitry of schizophrenia
A Carlsson
PHARMACOPSYCHIATRY (2006)
First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients
LS Pilowsky et al.
MOLECULAR PSYCHIATRY (2006)
Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders
S Marenco et al.
CNS DRUGS (2006)
Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats
Christina Kurre Olsen et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2006)
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia - A randomized, double-blind, placebo-controlled study
HY Lane et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia
T Sumiyoshi et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2005)
Prostaglandin-mediated control of rat brain kynurenic acid synthesis - opposite actions by COX-1 and COX-2 isoforms
L Schwieler et al.
JOURNAL OF NEURAL TRANSMISSION (2005)
Celecoxib augmentation of continuously Ill patients with schizophrenia
MH Rapaport et al.
BIOLOGICAL PSYCHIATRY (2005)
Tryptophan metabolism and oxidative stress in patients with Huntington's disease
N Stoy et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Clinical effects of COX-2 inhibitors on cognition in schizophrenia
N Müller et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2005)
N-methyl-D-aspartate receptors as a target for improved antipsychotic agents:: novel insights and clinical perspectives
MJ Millan
PSYCHOPHARMACOLOGY (2005)
Mechanism of action of antipsychotic drugs: From dopamine D-2 receptor antagonism to glutamate NMDA facilitation
M Laruelle et al.
CLINICAL THERAPEUTICS (2005)
Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia
CL Miller et al.
NEUROBIOLOGY OF DISEASE (2004)
Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms
T Sumiyoshi et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2004)
COX-2 inhibition as a treatment approach in schizophrenia:: Immunological considerations and clinical effects of celecoxib add-on therapy
N Müller et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2004)
Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia
I Kremer et al.
BIOLOGICAL PSYCHIATRY (2004)
Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia
O Yokota et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2004)
Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease
P Guidetti et al.
NEUROBIOLOGY OF DISEASE (2004)
Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia
T Numakawa et al.
HUMAN MOLECULAR GENETICS (2004)
Psychotropic effects of COX-2 inhibitors -: A possible new approach for the treatment of psychiatric disorders
N Müller et al.
PHARMACOPSYCHIATRY (2004)
Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex
L Schwieler et al.
SYNAPSE (2004)
The genetics of schizophrenia: glutamate not dopamine?
DA Collier et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins
E Aronica et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2003)
Tolerance, DCs and tryptophan: much ado about IDO
U Grohmann et al.
TRENDS IN IMMUNOLOGY (2003)
Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia
NM Williams et al.
MOLECULAR PSYCHIATRY (2003)
Modulation of group II metabotropic glutamate receptor signaling by chronic cocaine
ZX Xi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Manipulation of brain kynurenines: Glial targets, neuronal effects, and clinical opportunities
R Schwarcz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia
N Müller et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat
P Casolini et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2002)
Prostaglandins as modulators of immunity
SG Harris et al.
TRENDS IN IMMUNOLOGY (2002)
T-helper-1 and t-helper-2 responses in psychiatric disorders
MJ Schwarz et al.
BRAIN BEHAVIOR AND IMMUNITY (2001)
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia
S Erhardt et al.
NEUROSCIENCE LETTERS (2001)
Increased cortical kynurenate content in schizophrenia
R Schwarcz et al.
BIOLOGICAL PSYCHIATRY (2001)
A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia
DC Goff et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2001)
Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection
GJ Guillemin et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Interaction of the neuroprotective drug riluzole with GABAA and glycine receptor channels
B Mohammadi et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2001)
Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence
A Carlsson et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2001)
Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons
S Erhardt et al.
AMINO ACIDS (2001)
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia
LS Kegeles et al.
BIOLOGICAL PSYCHIATRY (2000)
Prostaglandin E2 increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2:: Regulation by interleukin-2, interleukin-10, and bovine leukemia virus
D Pyeon et al.
JOURNAL OF VIROLOGY (2000)
Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment
V Arolt et al.
MOLECULAR PSYCHIATRY (2000)
Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients
MJ Schwarz et al.
BIOLOGICAL PSYCHIATRY (2000)
分享论文
